Bank Pictet & Cie Europe AG Cuts Position in DexCom, Inc. $DXCM

Bank Pictet & Cie Europe AG decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 5.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 142,832 shares of the medical device company’s stock after selling 8,174 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in DexCom were worth $9,480,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of DexCom in the second quarter valued at approximately $26,000. SJS Investment Consulting Inc. lifted its position in shares of DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after buying an additional 384 shares in the last quarter. Financial Consulate Inc. purchased a new position in shares of DexCom during the 3rd quarter valued at approximately $29,000. CVA Family Office LLC grew its stake in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the period. Finally, ORG Partners LLC increased its holdings in DexCom by 124.3% in the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 0.7%

Shares of DXCM opened at $62.37 on Thursday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The stock has a market cap of $24.00 billion, a PE ratio of 29.70, a price-to-earnings-growth ratio of 1.22 and a beta of 1.55. The firm’s fifty day moving average is $69.56 and its two-hundred day moving average is $67.34. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. The business had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The company’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.45 earnings per share. Research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on DXCM shares. Piper Sandler restated an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Truist Financial reiterated a “buy” rating and issued a $80.00 target price (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price for the company in a research note on Tuesday, March 24th. Morgan Stanley restated an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Finally, Barclays reiterated an “underweight” rating and issued a $72.00 price objective (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.50.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $64.85, for a total value of $110,245.00. Following the completion of the sale, the executive vice president owned 112,904 shares in the company, valued at approximately $7,321,824.40. This represents a 1.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.